Development of PARP inhibitor combinations for castration resistant prostate cancer unselected for homologous recombination repair mutations.

ABSTRACT: Genetic instability is a hallmark of cancer and, with the introduction of poly (ADP-ribose) polymerase (PARP) inhibitors, is a targetable feature of many tumors. Currently, two PARP inhibitors, olaparib and rucaparib, have received approval as monotherapy by the Food and Drug Administration for the treatment of men with castration resistant prostate cancer with selected mutations involving the homologous recombination (HR) pathway. However, it is currently debated whether an HR mutation is a prerequisite for response or if patients with HR-proficient mCRPC may also benefit from their use when combined with other targeted or immunotherapeutic agents. Several large phase III trials of PARP inhibitors with novel androgen axis inhibitors in groups of unselected patients are underway. Additiona

SUBMITTER: McFarland TR 

PROVIDER: S-EPMC8340210 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature